Recent Insider Transactions Derivative • Aug 19
CEO & Director exercised options and sold US$326k worth of stock On the 17th of August, Reid Waldman exercised 3k options at a strike price of around US$12.19 and sold these shares for an average price of US$107 per share. This trade did not impact their existing holding. For the year to December 2024, Reid's total compensation was 5% salary and 95% other compensation. This indicates that these sales could comprise a meaningful part of their income for the year. Reid currently holds less than 1% of total shares outstanding. Company insiders have collectively sold US$23m more than they bought, via options and on-market transactions in the last 12 months. Recent Insider Transactions • Aug 16
Independent Non-Employee Director recently sold US$11m worth of stock On the 12th of August, John Childs sold around 100k shares on-market at roughly US$107 per share. This transaction amounted to 5.0% of their direct individual holding at the time of the trade. This was the largest sale by an insider in the last 3 months. This was the only on-market transaction from insiders over the last 12 months. Actualités en direct • Aug 11
Veradermics Reports Positive Phase 2 Results and Eyes Key Hair Loss Data in 2026 Veradermics reported positive topline results from its Phase 2 Study 207 of VDPHL01 in female pattern hair loss, citing rapid onset and consistent hair growth, and has completed enrollment in its pivotal Phase 2/3 Study 306 in the same indication, with topline data expected in the first half of 2027.
The company also flagged several late-2026 readouts, including topline data from a confirmatory Phase 3 study in men and 12‑month data from another Phase 2/3 study, which collectively increase the concentration of clinical risk and potential inflection points over the next 12 months.
Veradermics shares trade at $110.75, with the stock up 193.4% year to date, which suggests expectations around the hair loss franchise and upcoming data are already playing a significant role in how the market values the company.
The dense calendar of Phase 2, Phase 2/3 and Phase 3 readouts means trial outcomes could have a substantial effect on Veradermics, so considering position sizing and risk tolerance is important when evaluating this stock. Annonce • Jul 17
Veradermics Announces Presentation of Data from Subgroup Analysis of Phase 2/3 Study ‘302’ in Males with Pattern Hair Loss Veradermics, Incorporated announced the presentation of data from the Phase 2/3 Study ‘302’ of VDPHL01 in male patients with mild-to-moderate pattern hair loss. The subgroup analysis data were shared in a poster presentation on July 16, 2026, and will be shared in an oral presentation on July 17, 2026, during the 2026 American Academy of Dermatology Innovation Academy in New York City. Study ‘302’ is a randomized, double-blind, placebo-controlled Phase 2/3 trial evaluating treatment with VDPHL01, a proprietary extended-release oral minoxidil formulation, in over 500 males with mild-to-moderate pattern hair loss. The new data include results from an age-based subgroup analysis of the efficacy and safety of VDPHL01 in males less than 40 years of age. Oral presentation details: Title: Subgroup Analysis of the Efficacy and Safety of VDPHL01, a Novel Investigational Extended-Release (ER) Oral Minoxidil Tablet, in Male Patients with Pattern Hair Loss (PHL) by Age. Presentation Date/Time/Location: Friday, July 17, 2026, at 10:10 a.m. ET; Mercury Ballroom. VDPHL01 (extended-release minoxidil tablet) is a proprietary investigational, oral non-hormonal drug in Phase 3 development for pattern hair loss in both women and men. VDPHL01 leverages extended-release technology to deliver a minoxidil product with the potential for improved efficacy and safety. The proprietary extended-release formulation utilizes a gel matrix designed to deliver long-lasting, steady release of minoxidil for sustained absorption. VDPHL01 has been shown to avoid the high peak concentrations of immediate-release oral minoxidil, while extending time above the minimum hair growth threshold to increase time for hair to grow. If approved, VDPHL01 would be the only FDA-approved oral non-hormonal treatment for pattern hair loss in both male and female patients. VDPHL01 is protected by a broad library of patents and patent applications related to the key innovations of VDPHL01. The earliest expiring patent term is 2043. Pattern hair loss, also known as androgenetic alopecia, affects an estimated 80 million people in the United States (30 million women and 50 million men). Pattern hair loss can have a significant impact on quality of life, affecting an individual’s mental health and relationships. People with pattern hair loss often experience depression, low self-esteem, and social withdrawal. There have been no new FDA-approved prescription medicines for pattern hair loss in nearly 30 years. In addition, current treatments include over-the-counter “nutraceuticals” that produce inconsistent results and contribute to high dissatisfaction among participants and healthcare providers. The prevalence of pattern hair loss and the market demand for new treatments contribute to making it the largest aesthetics market worldwide, projected to reach approximately $30 billion by 2028. Annonce • Jul 16
Veradermics, Incorporated Announces Positive Topline Results From Open-Label Phase 2 Clinical Trial Study 207 Evaluating VDPHL01 In Female Pattern Hair Loss Veradermics, Incorporated had announced positive topline results from its open-label Phase 2 clinical trial (Study ‘207’) evaluating VDPHL01, a proprietary extended-release oral minoxidil formulation, in females with mild-to-moderate pattern hair loss. VDPHL01 has the potential to become the first FDA-approved oral treatment for female pattern hair loss. Among female participants who received either VDPHL01 4.5mg once daily or VDPHL01 4.5mg twice daily for 6 months, VDPHL01 demonstrated a potentially differentiated clinical profile defined by rapid onset of activity, consistent response across participants, and increases in hair count while being generally well tolerated with no treatment-related serious adverse events (SAEs) and no adverse events of special interest (AESIs) of cardiac origin. In the study, VDPHL01 achieved consistent hair growth on the endpoint of non-vellus target area hair count (TAHC) and patient reported outcome (PRO) benefits of ‘improved’ or ‘much improved’ on the Androgenetic Alopecia Impact Rating Scale (AAIRS) at Month 6. Participants achieved an average increase in non-vellus hair count of 22.7 hairs/cm² and 23.3 hairs/cm² in once daily and twice daily VDPHL01 treatment arms, respectively. Additionally, 88.9% of participants in the once daily dose arm and 90.0% of participants in the twice daily dose arm achieved ‘improved’ or ‘much improved’ hair coverage on the AAIRS. The consistency of clinically meaningful hair growth reported by participants was further supported by investigator perception of hair growth, with investigators grading 100% (once daily dosing arm) and 90% (twice daily dosing arm) of female participants as having improvement in hair coverage at Month 6. Fast onset of hair growth was also observed by investigators and patients as early as Month 2, the earliest measured time point measured in the trial, with 67.2% of participants graded by investigators as demonstrating improvement and 63.2% of participants reporting improvement in hair coverage at Month 2. Treatment with VDPHL01 was generally well tolerated through Month 6 with an overall safety profile consistent with prior studies with VDPHL01. No treatment-related SAEs and no AESIs of cardiac origin were observed in this study. VDPHL01 is currently being evaluated in an extensive pivotal development program designed to support the approval of VDPHL01 in both female and male pattern hair loss. Veradermics is actively recruiting female participants for its female pattern hair loss Phase 2/3 trial, Study ‘306’, with topline data anticipated in First Half 2027. In April, Veradermics announced topline results from Study ‘302’, a registration-directed Phase 2/3 trial in male pattern hair loss and, in February, Veradermics announced enrollment completion in its second Phase 3 male trial, Study ‘304’, with topline results anticipated in the second half of 2026. VDPHL01 (extended-release minoxidil tablet) is a proprietary investigational, oral non-hormonal drug in Phase 3 development for pattern hair loss in both women and men. VDPHL01 leverages extended-release technology to deliver a minoxidil product with the potential for improved efficacy and safety. The proprietary extended-release formulation utilizes a gel matrix designed to deliver long-lasting, steady release of minoxidil for sustained absorption. VDPHL01 has been shown to avoid the high peak concentrations of immediate-release oral minoxidil, while extending time above the minimum hair growth threshold to increase time for hair to grow. If approved, VDPHL01 would be the only FDA-approved oral non-hormonal treatment for pattern hair loss in both male and female patients. VDPHL01 is protected by a broad library of patents and patent applications related to the key innovations of VDPHL01. The earliest expiring patent term is 2043. Pattern hair loss, also known as androgenetic alopecia, affects an estimated 80 million people in the United States (30 million women and 50 million men). Pattern hair loss can have a significant impact on quality of life, affecting an individual’s mental health and relationships. People with pattern hair loss often experience depression, low self-esteem, and social withdrawal. There have been no new FDA-approved prescription medicines for pattern hair loss in nearly 30 years. In addition, current treatments include over the counter “nutraceuticals” that produce inconsistent results and contribute to high dissatisfaction among participants and healthcare providers. The prevalence of pattern hair loss and the market demand for new treatments contribute to making it the largest aesthetics market worldwide, projected to reach approximately $30 billion by 2028. Study ‘207’ is a multicenter Phase 2 open label study in 21 adult male and 28 adult female pattern hair loss patients to obtain proof of concept for the safety and efficacy of twelve months of treatment with VDPHL01 8.5 mg twice daily in male patients and VDPHL01 4.5 mg either once or twice daily in female patients with pattern hair loss. Actualités en direct • May 21
Veradermics Shows Strong Hair Growth Results and Raises US$767 Million for Lead Treatment Veradermics reported positive topline Phase 2/3 results for VDPHL01, an extended-release oral minoxidil tablet, showing robust and rapid hair growth with a favorable safety profile in males with pattern hair loss.
The company completed enrollment in its pivotal Phase 3 Study 304 for males and is actively enrolling females in Study 306, with additional data readouts expected in the second half of 2026.
Veradermics raised about US$766.8 million through an upsized IPO, follow-on offerings, and private placements, and reported a net loss of US$27.2 million in Q1 2026 tied to higher research and development spending.
These developments position Veradermics as a focused late-stage clinical company in hair loss treatment, with substantial capital earmarked to fund operations into 2030 and to support ongoing clinical programs.
Investors may want to monitor future trial readouts and any regulatory updates, while keeping in mind that the company is still loss-making and dependent on successful clinical and commercial execution for its lead candidate. Annonce • Apr 28
Veradermics, Incorporated has filed a Follow-on Equity Offering. Veradermics, Incorporated has filed a Follow-on Equity Offering.
Security Name: Common Stock
Security Type: Common Stock
Securities Offered: 3,350,000 Annonce • Feb 10
Veradermics, Incorporated Completes Enrollment in Second Pivotal Phase 3 Clinical Trial of VDPHL01 for Male Pattern Hair Loss Veradermics, Incorporated announced completion of enrollment in its second Phase 3 registration-directed clinical trial evaluating VDPHL01 for the treatment of male pattern hair loss. Following the previously announced completion of enrollment in Veradermics' first Phase 2/3 trial, this milestone marks the completion of enrollment across both Phase 3 clinical trials of VDPHL01 in males, encompassing more than 1,000 participants. Investors are cautioned not to place undue reliance on these forward-looking statements, including statements regarding the timing of completion of and data from the Phase 3 clinical trials for VDPHL01 for thetreatment of male and female pattern hair loss; the release profile of VDPHL01 and whether the release profile will achieve its intended effect; whether Veradermics will successfully file a new drug application for VDPHL01; and the projected size of the market for pattern hair loss treatments. Veradermics' anticipation that its success will depend on the approval and successful commercialization of VDPHL01, which is its lead product candidate, and if Veradermics is unable to obtain regulatory approval for, and successfully commercialize, VDPHL01, or any other current or future product candidates, or experience significant delays in doing so, its business will be materially harm; risks related to preclinical and clinical development and that results of earlier studies and trials may not be predictive of future preclinical studies or clinical trial results; the risk that Veradermics may encounter substantial delays in preclinical and clinical trials, or may not be able to conduct or complete preclinical or clinical trials on the expected timelines, if at all; the risk that the U.S. Food and Drug Administration does not conclude that VDPHL01 satisfies the requirements for the Section 505(b)(2) regulatory approval pathway, or if the requirements for VDPHL01 under Section 505(b)(2") are not as Veradermics expects, the approval pathway for those product candidates takes longer or costs more than anticipated; the risk that adverse events or undesirable side effects are caused by Veradermics' product candidates; competition from other companies; risks related to developing Veradermics' sales, marketing and distribution capability; the risk that even if Veradermics obtains regulatory approval for VDPHL01 or any other product candidates, such products may fail to achieve market acceptance; the risk that the commercial opportunity for VDPHL01 or Any other current or future product candidates may be smaller than Veradermics expects; the cash-pay healthcare market for VDPHL01 may limit Veradermics' ability to increase sales or achieve profitability; risks relating to effectively maintaining, promoting and enhancing Veradermics' reputation and VDPHL01 brand recognition in a cost-effective manner; risks related to Veradermics' need to grow its organization; the ability of Veradermics to successfully execute its intellectual property strategy for VDPHL01 and risks related to Veradermic' need to grow its organization. the ability of Veradermic to successfully execute its intellectual property strategies for VDPHL01 and risk related to Veradermics's ability to obtain and maintain sufficient intellectual property protection for VDPHL01 and other current and any future product candidates and other proprietary technologies; risks related to ongoing regulatory obligations for any approved products; risks related to Verader mics' reliance on third parties for the manufacture of drug or biological substances for preclinical studies and clinical trials and expectations that Veradermics will continue to do so for commercialization of any product candidates that are approved for marketing; risks related to VeraderMics' reliance and expected continued reliance on third parties to conduct preclinical studies and clinical trials; global macro conditions; global macro and regulatory obligations for any approved products. Annonce • Feb 04
Veradermics, Incorporated has completed an IPO in the amount of $256.319999 million. Veradermics, Incorporated has completed an IPO in the amount of $256.319999 million.
Security Name: Common Stock
Security Type: Common Stock
Securities Offered: 15,077,647
Price\Range: $17
Transaction Features: Sponsor Backed Offering